BRPI0715740A8 - Agente redutor de triglicerídeos séricos - Google Patents

Agente redutor de triglicerídeos séricos

Info

Publication number
BRPI0715740A8
BRPI0715740A8 BRPI0715740A BRPI0715740A BRPI0715740A8 BR PI0715740 A8 BRPI0715740 A8 BR PI0715740A8 BR PI0715740 A BRPI0715740 A BR PI0715740A BR PI0715740 A BRPI0715740 A BR PI0715740A BR PI0715740 A8 BRPI0715740 A8 BR PI0715740A8
Authority
BR
Brazil
Prior art keywords
serum triglyceride
triglyceride lowering
agent
lowering agent
bacilius
Prior art date
Application number
BRPI0715740A
Other languages
English (en)
Inventor
Suzuki Hiromi
Fujiwara Shigeru
Original Assignee
Calpis Co Ltd
Asahi Calpis Wellness Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calpis Co Ltd, Asahi Calpis Wellness Co Ltd filed Critical Calpis Co Ltd
Publication of BRPI0715740A2 publication Critical patent/BRPI0715740A2/pt
Publication of BRPI0715740A8 publication Critical patent/BRPI0715740A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

AGENTE REDUTOR DE TRIGLICERÍDEOS SÉRICOS A presente invenção refere-se a agentes farmacêuticos e produtos alimentares que não têm efeitos colaterais, são fáceis de ingerir continuamente e têm um efeito redutor de triglicerídeos séricos. Apresentam-se um agente para melhorar o metabolismo lipidico e um agente redutor de triglicerídeos séricos, cada um compreendendo, como um ingrediente ativo, uma cultura de uma bactéria pertencente ao gênero Bacilius. A bactéria pertencente ao gênero Bacilius é, de preferência, Baclilus subtilis, e, mais preferivelmente, Bacilius subtilis C-3102 (FERM BP-1096). O agente para melhorar o metabolismo lipídico e o agente redutor de triglicerídeos séricos são utilizáveis para o tratamento e prevenção de doenças como arteriosclerose.
BRPI0715740A 2006-08-21 2007-08-14 Agente redutor de triglicerídeos séricos BRPI0715740A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006224672 2006-08-21
JP2006-224672 2006-08-21
PCT/JP2007/065848 WO2008023608A1 (fr) 2006-08-21 2007-08-14 Agent d'amélioration du métabolisme lipidique

Publications (2)

Publication Number Publication Date
BRPI0715740A2 BRPI0715740A2 (pt) 2013-07-16
BRPI0715740A8 true BRPI0715740A8 (pt) 2017-01-24

Family

ID=39106694

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0715740A BRPI0715740A8 (pt) 2006-08-21 2007-08-14 Agente redutor de triglicerídeos séricos

Country Status (10)

Country Link
US (2) US20100183576A1 (pt)
EP (1) EP2060263A4 (pt)
JP (1) JP5113057B2 (pt)
KR (1) KR101454228B1 (pt)
CN (1) CN101511377B (pt)
BR (1) BRPI0715740A8 (pt)
CA (1) CA2661373C (pt)
MX (1) MX2009001782A (pt)
TW (1) TW200817020A (pt)
WO (1) WO2008023608A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012023042A2 (pt) * 2010-03-12 2016-05-17 Calpis Co Ltd agente para aumentar as bifidobactérias e reduzir a diminuição das bifidobactérias no intestino grosso
JP6302183B2 (ja) * 2013-07-12 2018-03-28 株式会社エンザミン研究所 アディポサイトカイン産生バランス調整剤及び脂肪組織の炎症・酸化ストレス抑制剤並びに脂肪組織のマクロファージ浸潤抑制剤
CN107073047B (zh) * 2014-10-28 2021-08-24 株式会社恩基美研究所 胰岛素抵抗改善剂
CN114634892A (zh) * 2022-03-24 2022-06-17 浙江省农业科学院 具有降血脂作用的益生菌组合物、制备方法及设备

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63209580A (ja) * 1987-02-25 1988-08-31 Karupisu Shokuhin Kogyo Kk バチルス・ズブチリスｃ−３１０２
JPH0424022A (ja) 1990-05-21 1992-01-28 Hitachi Medical Corp 移動形ｘ線装置
US5776756A (en) * 1995-08-31 1998-07-07 Toyo Hakko Co., Ltd. Fermentation compositions having superoxide dismutating activity and an antihypertensive agent for treatment of constipation each having the superoxide dismutating activity
WO1997031546A1 (en) * 1996-02-29 1997-09-04 Nutri Pharma As Composition and its use as a food supplement or for lowering lipids in serum
JP3489930B2 (ja) * 1996-03-08 2004-01-26 株式会社ヤクルト本社 がん予防食品
JPH10234326A (ja) * 1997-02-26 1998-09-08 Yusuke Sugaya 新規な大豆加工食品
ATE314858T1 (de) * 1998-04-01 2006-02-15 Ganeden Biotech Inc Erfahren zür verringerung von cholesterin mit bacillus coagulans sporen, systeme un zusammensetzungen
US6811786B1 (en) * 1999-04-01 2004-11-02 Ganeden Biotech, Inc. Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions
BR9915693A (pt) * 1998-11-25 2001-08-14 Nutri Pharma As Composição compreendendo proteìna de soja, fibra de dieta e um composto fitoestrogênio e seu uso na prevenção e/ou tratamento de diabetes tipo 2, a sìdrome metabólica e doenças cardiovasculares associadas
JP2004111573A (ja) * 2002-09-17 2004-04-08 Sony Corp 半導体装置、及び同半導体装置の製造方法
JP4309108B2 (ja) * 2002-09-26 2009-08-05 大和薬品株式会社 糖尿病治療薬
JP4503951B2 (ja) * 2003-08-06 2010-07-14 株式会社琉球バイオリソース開発 糖尿病疾患予防・治療剤
JP4001239B2 (ja) * 2004-01-23 2007-10-31 国立大学法人京都大学 ダイズ由来ペプチド混合物およびその利用
JP2006111573A (ja) * 2004-10-14 2006-04-27 Ee H C:Kk バチルス・サブチルス菌株の使用及びその使用に用いられる菌株を含む食品
JP2006151952A (ja) 2004-11-05 2006-06-15 Oto Corporation:Kk 高脂血症乃至高尿酸血症改善剤、及び、健康食品

Also Published As

Publication number Publication date
EP2060263A1 (en) 2009-05-20
JPWO2008023608A1 (ja) 2010-01-07
BRPI0715740A2 (pt) 2013-07-16
WO2008023608A1 (fr) 2008-02-28
US20130017181A1 (en) 2013-01-17
EP2060263A4 (en) 2012-01-25
CA2661373C (en) 2014-10-07
CN101511377B (zh) 2012-10-03
US20100183576A1 (en) 2010-07-22
TW200817020A (en) 2008-04-16
CN101511377A (zh) 2009-08-19
JP5113057B2 (ja) 2013-01-09
MX2009001782A (es) 2009-02-25
CA2661373A1 (en) 2008-02-28
KR101454228B1 (ko) 2014-10-23
KR20090059124A (ko) 2009-06-10

Similar Documents

Publication Publication Date Title
Mobasheri et al. Osteogenic effects of resveratrol in vitro: potential for the prevention and treatment of osteoporosis
BR112014032905A2 (pt) métodos de redução do risco de um evento cardiovascular em um sujeito em terapia com estatina
BR112012006692A2 (pt) composição farmacêutica compreendendo ácido graxo de omega-3 e um derivado de hidróxi de uma estatina e métodos de uso das mesmas
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
CO6341563A2 (es) Compuestos organicos
MX2011008448A (es) Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia.
MX2016011975A (es) Metodos para reducir el riesgo cardiovascular.
BRPI0513082A (pt) formulações de fenofibrato e métodos de tratamento relacionados
EP3318262A3 (en) Composition for preventing or treating bone disease, obesity and lipid-related metabolic disease
EA200970374A1 (ru) Лечение антиаритмическими средствами и омега-3 жирными кислотами и их комбинированным продуктом
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
WO2009099830A3 (en) Edible film-strips for immediate release of active ingredients
NO20080855L (no) Behandling med azetidinon-baserte kolesterol absorpsjonsinhibitorer og omega-3 fettsyrer og et kombinasjonsprodukt derav
BR112018003842A2 (pt) método para inibir a absorção de lipídios e/ou promover a excreção de lipídios utilizando d-psicose
NO20074318L (no) Anvendelse av en fettsyresammensetning som inneholder DHA for fremstilling av et medisinsk produkt eller et naeringsmiddel for behandling av amyloidoserelaterte sykdommer
UA101903C2 (ru) Лекарственное средство на основе дииндолилметана для лечения гиперпластических и воспалительных заболеваний
BR112015000321A2 (pt) formulações de laquinimod sem agente alcalinizante
EP3318251A3 (en) Composition for preventing or treating obesity or lipid-related metabolic disease
BR112015027631A2 (pt) Métodos para melhorar perfis de lipídeo usando atrasentana
BRPI0715740A8 (pt) Agente redutor de triglicerídeos séricos
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
BR112017011122A2 (pt) ?composições, métodos in vitro e in vivo para a inibição de uma enzima, método não terapêutico para a redução do peso, método para a redução da absorção calórica, métodos para o tratamento ou prevenção da obesidade e da hiperglicemia e/ou hiperlipidemia em um sujeito e utilização de uma composição?
BR112013003064A2 (pt) agente profilático ou terapêutico para a esteato-hepatite não alcoólica
EP2382978A3 (en) Modulation of the immune system by inositol phospholipids
BRPI0700133A (pt) composição farmacêutica compreendendo tramadol e cetoprofeno em combinação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: ASAHI CALPIS WELLNESS CO., LTD. (JP)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2475 DE 12-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.